Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Hepatocellular carcinoma (HCC) is the most common form of liver cancer, which often arises from previous liver pathologies such as HBV, HCV, and alcohol abuse. It is typically associated with an enlarged cirrhotic organ. In this study, we analyzed tumor and distal tissues from a patient who underwent liver resection for HCC with no previous pathologies and whose liver showed normal function without signs of cirrhosis. Genetic analysis of mitochondrial DNA (mtDNA) revealed a novel variant of the gene encoding the NADH dehydrogenase subunit 6 (ND6) protein in the tumor tissue. The deletion of a thymidine generated an early stop codon, resulting in a truncated form of the protein (ΔND6) with 50% of the C-terminal primary sequence missing. ND6 is a subunit of the NADH dehydrogenase complex, also known as Complex I, the largest complex in the electron transport chain. Previous studies have linked mtDNA Complex I mutations to mitochondrial disorders and cancer. Through biochemical analyses, we characterized this new mutation and showed that the expression of ΔND6 negatively affects the stability and functionality of Complex I. Data were confirmed by molecular dynamics simulations suggesting conformational rearrangements, overall revealing a leading role of ND6 in the assembly of Complex I.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11954883PMC
http://dx.doi.org/10.1038/s41598-025-91746-xDOI Listing

Publication Analysis

Top Keywords

hepatocellular carcinoma
8
nadh dehydrogenase
8
complex
7
characterization mutation
4
mutation mitochondrial
4
nd6
4
mitochondrial nd6
4
nd6 gene
4
gene hepatocellular
4
carcinoma effects
4

Similar Publications

This study aimed to create multifunctional nanoparticles (NPs), specifically AS1411@MPDA-Len-Cy5.5 (AMLC), for the purpose of developing effective strategies for treating hepatocellular carcinoma (HCC) through targeted therapy and photothermal therapy (PTT). The study involved synthesizing mesoporous polydopamine (MPDA)-NPs, loading lenvatinib (Len) and Cy5.

View Article and Find Full Text PDF

Objective: Anoikis is an anchorage-dependent programmed cell death implicated in multiple pathological processes of cancers; however, the prognostic value of anoikis-related genes (ANRGs) in hepatocellular carcinoma (HCC) remains unclear. Our study aims to develop an ANRGs-based prediction model to improve prognostic assessment in HCC patients.

Methods: The RNA-seq profile was performed to estimate the expression of ANRGs in HCC patients.

View Article and Find Full Text PDF

Purpose: This study aimed to evaluate the clinical efficiency and safety of hepatic arterial infusion chemotherapy (HAIC) combined with lenvatinib and programmed cell death protein-1 (PD-1) inhibitor for patients with hepatocellular carcinoma (HCC) and lung metastasis.

Methods: In this multicenter retrospective study, treatment-naive patients with advanced (BCLC stage C) HCC and lung metastases who received lenvatinib and PD-1 inhibitor - with or without HAIC - between January 2019 and January 2024 were reviewed. Propensity score matching (PSM) was applied to balance baseline characteristics between the two groups.

View Article and Find Full Text PDF

Hepatocellular carcinoma (HCC) is a prevalent malignant neoplasm of the digestive system, including 80% of primary liver malignancies. The Wnt/β-catenin signaling pathway plays a key role in immune response and tumer resistance. A growing number of studies have shown that the Wnt/β-catenin signaling pathway is involved in the pathogenesis of HCC.

View Article and Find Full Text PDF

Objectives: Hepatocellular carcinoma is the fourth leading cause of cancer-related mortality worldwide, and almost all patients have simultaneous cirrhosis. For patients with hepatocellular carcinoma concurrent with cirrhosis, the best treatment option is liver transplant. With expansion of transplant criteria and increased use of liver transplant for treatment, median survival and recurrence rates in patients with hepatocellular carcinoma have also increased.

View Article and Find Full Text PDF